At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 91 enrolled
Drug / intervention
montelukast sodium +2 moredrug
Likely dose
montelukast sodium 7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MK-476 IV Formulation Phase III Open Label Exploratory Comparative Study - Acute Exacerbations of Asthma -
In Brief
A Phase 3 clinical trial evaluating montelukast sodium and aminophylline hydrate for Asthma. Completed, enrolled 91 participants.
Detailed Summary
The study estimates the efficacy and safety of MK0476 and aminophylline intravenous administration in adult participants with acute asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartMar 2007
Primary CompletionAug 2007
TodayJul 2026
First PostedMar 1, 2007
Enrollment StartMar 1, 2007
Primary CompletionAug 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 19.3 years ago
Interventions
montelukast sodiumdrug
Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
montelukast sodiumdrug
Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
aminophylline hydratedrug
Aminophylline 250 mg IV drip infusion over 60 minutes